Literature DB >> 22516245

α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.

Hiroko Ikeda1, Yasunori Sato, Norihide Yoneda, Kenichi Harada, Motoko Sasaki, Seiko Kitamura, Yoshiko Sudo, Akishi Ooi, Yasuni Nakanuma.   

Abstract

α-Fetoprotein is expressed in hepatocellular carcinoma, yolk sac tumor, and some gastric carcinomas. The α-fetoprotein-producing gastric carcinoma composed of hepatoid and common adenocarcinoma shows morphological similarities to combined hepatocellular and cholangiocarcinoma. In this study, the expression of putative hepatic stem/progenitor markers (EpCAM, OV-6, DLK-1, and NCAM/CD56), hepatocyte markers (HepParI, α-fetoprotein, glypican 3), and the germ cell marker SALL4 was examined in α-fetoprotein-producing gastric carcinoma (20 cases) and combined hepatocellular and cholangiocarcinoma (20 cases) for evaluation of pathologic differentiation and also the histogenesis of both tumors. The SALL4 protein was expressed in 95% of α-fetoprotein-producing gastric carcinoma, including the hepatoid component (hepatoid gastric carcinoma), but was absent in combined hepatocellular and cholangiocarcinoma. Glypican 3 and α-fetoprotein were detected in all hepatoid-type α-fetoprotein-producing gastric carcinoma but variably in combined hepatocellular and cholangiocarcinoma. NCAM/CD56 was expressed focally in combined hepatocellular and cholangiocarcinoma but was rare in hepatoid gastric carcinoma. EpCAM, DLK-1, and OV6 were variably expressed in hepatoid gastric carcinoma and combined hepatocellular and cholangiocarcinoma. SALL4 was a useful differential marker for combined hepatocellular and cholangiocarcinoma and hepatoid gastric carcinoma. The histogenesis of hepatoid gastric carcinoma expressing SALL4 seems to reflect fetal gut differentiation or involve the germ cell lineage and may be different from that of combined hepatocellular and cholangiocarcinoma involving the hepatic stem cell or progenitor cell lineages. In conclusion, hepatoid gastric carcinoma and combined hepatocellular and cholangiocarcinoma shared morphologies, whereas the distinction of hepatoid gastric carcinoma from combined hepatocellular and cholangiocarcinoma is possible by immunostaining for SALL4. These 2 tumors seem to differ in their histogenesis with respect to SALL4 expression.1.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22516245     DOI: 10.1016/j.humpath.2011.11.022

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  Clinicopathologic and immunohistochemical characteristics of gastric adenocarcinoma with enteroblastic differentiation: a study of 29 cases.

Authors:  Takashi Murakami; Takashi Yao; Hiroyuki Mitomi; Takashi Morimoto; Hiroya Ueyama; Kenshi Matsumoto; Tsuyoshi Saito; Taro Osada; Akihito Nagahara; Sumio Watanabe
Journal:  Gastric Cancer       Date:  2015-04-18       Impact factor: 7.370

2.  Liver Metastases of Neuroendocrine Tumors Rarely Show Overlapping Immunoprofile with Hepatocellular Carcinomas.

Authors:  Ming Jin; Xiaoping Zhou; Martha Yearsley; Wendy L Frankel
Journal:  Endocr Pathol       Date:  2016-09       Impact factor: 3.943

Review 3.  SALL4, the missing link between stem cells, development and cancer.

Authors:  Hiro Tatetsu; Nikki R Kong; Gao Chong; Giovanni Amabile; Daniel G Tenen; Li Chai
Journal:  Gene       Date:  2016-02-16       Impact factor: 3.688

4.  SALL4 expression in germ cell and non-germ cell tumors: a systematic immunohistochemical study of 3215 cases.

Authors:  Markku Miettinen; Zengfeng Wang; Peter A McCue; Maarit Sarlomo-Rikala; Janusz Rys; Wojciech Biernat; Jerzy Lasota; Yi-Shan Lee
Journal:  Am J Surg Pathol       Date:  2014-03       Impact factor: 6.394

5.  SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases.

Authors:  Ta-Chiang Liu; Neeta Vachharajani; William C Chapman; Elizabeth M Brunt
Journal:  Am J Surg Pathol       Date:  2014-07       Impact factor: 6.394

6.  Importance of SALL4 in the development and prognosis of hepatocellular carcinoma.

Authors:  Fei Yin; Xin Han; Shu-Kun Yao; Xiao-Ling Wang; Hui-Chai Yang
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

7.  Expression and clinical significance of SALL4 and β-catenin in colorectal cancer.

Authors:  Liliang Hao; Yan Zhao; Zhen Wang; Hongzhuan Yin; Xin Zhang; Tao He; Shanshan Song; Shaolong Sun; Baosheng Wang; Zhijie Li; Qi Su
Journal:  J Mol Histol       Date:  2016-01-16       Impact factor: 2.611

8.  SALL4 Expression in Hepatocellular Carcinomas Is Associated with EpCAM-Positivity and a Poor Prognosis.

Authors:  Hyunjin Park; Hyejung Lee; An Na Seo; Jai Young Cho; Young Rok Choi; Yoo-Seok Yoon; Ho-Seong Han; Young Nyun Park; Haeryoung Kim
Journal:  J Pathol Transl Med       Date:  2015-08-10

9.  Expression of transcript factors SALL4 and OCT4 in a subset of non-small cell lung carcinomas (NSCLC).

Authors:  Erika Rodriguez; Li Chen; Ming-Hui Ao; Susan Geddes; Ed Gabrielson; Frederic Askin; Hui Zhang; Qing Kay Li
Journal:  Transl Respir Med       Date:  2014-10-02

Review 10.  Hepatoid adenocarcinoma of the stomach--proper identification and treatment remain a challenge.

Authors:  Jon Arne Søreide; Ole Jacob Greve; Einar Gudlaugsson; Svein Størset
Journal:  Scand J Gastroenterol       Date:  2016-01-05       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.